Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2025-07-02 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des mod
Regulatory Filings Classification · 95% confidence The document is a press release from Inventiva announcing the publication of scientific research results in the 'Journal of Hepatology Reports'. It details findings from a Phase 2b clinical study and preclinical models regarding the drug lanifibranor. It does not constitute a formal financial report (10-K, IR), a conference call transcript (CT), or a regulatory filing of a mandatory nature. As it is a standard corporate announcement regarding research publication and scientific data, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-07-02 French
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of
Regulatory Filings Classification · 95% confidence The document is a press release issued by Inventiva announcing the publication of scientific research results in the 'Journal of Hepatology Reports'. It summarizes the findings of a clinical trial and preclinical studies regarding their drug candidate, lanifibranor. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate announcement of scientific progress. Under the provided categories, general corporate announcements that do not fit into specific financial reporting categories are classified as Regulatory Filings (RNS).
2025-07-02 English
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclarations de franchissements de seuils (article L. 233-7 du code de commerce)" and details a change in share ownership thresholds crossed by J.P. Morgan Chase & Co. in the company INVENTIVA. This type of filing, reporting changes in significant share ownership (crossing thresholds), directly corresponds to the definition of Major Shareholding Notification (MRQ). The document explicitly mentions crossing thresholds (5% of capital and voting rights) and the date of the crossing (May 23, 2025). The short length (1856 chars) is typical for a regulatory notification rather than a full report.
2025-06-17 French
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Board/Management Information Classification · 100% confidence The document is titled "Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors." The content explicitly discusses the appointment of a new director, approved by shareholders at the recent Annual General Meeting. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. Although the AGM is mentioned, the primary focus is the board appointment, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2025-06-10 English
Inventiva Participera à la « Jefferies Global Healthcare Conference » et à la « UBS Spring Biotech Conference »
Regulatory Filings Classification · 99% confidence The document is a press release announcing that the company's management team will participate in two investor conferences in June 2025: the 'Jefferies Global Healthcare Conference' and the 'UBS Spring Biotech Conference'. It specifies the dates, times, and locations, and mentions that a presentation will be webcast live and a replay will be available. This type of announcement, detailing management's schedule for meeting with investors at industry conferences, is best classified as an Investor Presentation (IP) announcement or related material, as it directly relates to investor engagement and presentation schedules, although it is not the presentation itself. However, since the core content is about participation in investor conferences where presentations/discussions occur, and given the available codes, 'IP' (Investor Presentation) is the most fitting category for materials related to scheduled investor presentations, or 'RPA' (Report Publication Announcement) if interpreted strictly as an announcement about an upcoming event/presentation. Given the context of financial conferences, 'IP' is often used for related communications. Since it is an announcement about participation in investor events, and not a formal regulatory report, 'IP' is the strongest fit among the specific options, as it relates to investor outreach activities. If it were purely a notice of a report release, RPA would be better, but this is about conference participation.
2025-05-27 French
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Regulatory Filings Classification · 100% confidence The document is a press release dated May 27, 2025, announcing that Inventiva's management will participate in two upcoming investor conferences in June 2025: the Jefferies Global Healthcare Conference and the UBS Spring Biotech Conference. It details the dates, locations, and mentions that a fireside chat will be webcast live. This type of announcement, informing investors about management's schedule for meeting with analysts and investors at industry events, is typically classified as an Investor Presentation (IP) or related communication, as it directly relates to investor engagement activities. However, since the document itself is an announcement *about* future presentations/meetings rather than the presentation material itself, and it is not a standard regulatory filing (like 10-K or ER), it fits best under the category related to investor engagement materials. Given the options, 'Investor Presentation' (IP) is the closest fit for content related to scheduled investor meetings and presentations, even though this is the announcement of attendance rather than the presentation slides themselves. If the document were solely about the *timing* of a report release, RPA would apply, but this is about conference participation.
2025-05-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.